NASDAQ : TVGN
Tevogen Bio Holdings Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 92.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 92.85M |
| Enterprise Value | 101.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 15.74M |
| Shares Outstanding | 15.74M |
| Shares Change (YoY) | +13.23% |
| Shares Change (QoQ) | +9.84% |
| Owned by Insiders (%) | 87.08% |
| Owned by Institutions (%) | 0.78% |
| Float | 2.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.33 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.74 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -297.37% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 1,504.24% |
| Weighted Average Cost of Capital (WACC) | 5.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -80.84% |
| 50-Day Moving Average | 6.94 |
| 200-Day Moving Average | 8.23 |
| Relative Strength Index (RSI) | 37.35 |
| Average Volume (20 Days) | 9,638 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 55,420 |
| Short Previous Month | 55,589 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 2.72% |
| Short Ratio (days to cover) | 10.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.40M |
| Pretax Income | -21.61M |
| Net Income | -22.24M |
| EBITDA | -21.28M |
| EBIT | -21.40M |
| Earnings Per Share (EPS) | -$6.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.08M |
| Total Debt | 9.44M |
| Net Cash | -8.36M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | -8.89M |
| Book Value Per Share | -4.16 |
| Working Capital | -4.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.57M |
| Capital Expenditures | -64,439 |
| Depreciation & Amortization | 119,115 |
| Net Borrowing | 2.00M |
| Free Cash Flow | -11.63M |
| FCF Per Share | -$0.74 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.23% |
| Shareholder Yield | -13.23% |
| Earnings Yield | -107.14% |
| FCF Yield | -12.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |